NASDAQ:VYGR - Voyager Therapeutics Stock Price, Price Target & More

$17.85 -0.75 (-4.03 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$17.85
Today's Range$17.76 - $18.88
52-Week Range$8.10 - $31.91
Volume403,565 shs
Average Volume425,847 shs
Market Capitalization$617.73 million
P/E Ratio-6.76
Dividend YieldN/A
Beta2.97

About Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics logoVoyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program, for tauopathies, including Alzheimer's disease, PSP, and FTD; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with AbbVie Inc.; Sanofi Genzyme; and the University of Massachusetts. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VYGR
CUSIPN/A
Phone857-259-5340

Debt

Debt-to-Equity RatioN/A
Current Ratio10.81%
Quick Ratio10.81%

Price-To-Earnings

Trailing P/E Ratio-6.76
Forward P/E Ratio-7.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$10.14 million
Price / Sales56.70
Cash FlowN/A
Price / CashN/A
Book Value$4.26 per share
Price / Book4.19

Profitability

EPS (Most Recent Fiscal Year)($2.64)
Net Income$-70,690,000.00
Net Margins-697.03%
Return on Equity-63.18%
Return on Assets-42.88%

Miscellaneous

Employees88
Outstanding Shares32,210,000

How to Become a New Pot Stock Millionaire

Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics (NASDAQ:VYGR) issued its earnings results on Wednesday, March, 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.32. The business had revenue of $6.35 million for the quarter, compared to the consensus estimate of $5.81 million. Voyager Therapeutics had a negative return on equity of 63.18% and a negative net margin of 697.03%. View Voyager Therapeutics' Earnings History.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Voyager Therapeutics.

What price target have analysts set for VYGR?

11 Wall Street analysts have issued 12-month target prices for Voyager Therapeutics' stock. Their forecasts range from $12.00 to $40.00. On average, they expect Voyager Therapeutics' share price to reach $30.10 in the next year. View Analyst Ratings for Voyager Therapeutics.

What are Wall Street analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:
  • 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (3/20/2018)
  • 2. Canaccord Genuity analysts commented, "We note, however, that the IND acceptance is a key step that allows VYGR to start its pivotal Phase 2-3 trial program per plan in 2Q18. VYGR has several potential catalysts coming up over the course of 2018 (see Table 1 on page 2 for details). Specifically, in our view, longer-term Phase 1b data (readouts over 2018) could favorably support the continued development of VY-AADC in advanced PD, and we are reiterating our BUY ahead of the availability of these data." (1/23/2018)
  • 3. Chardan Capital analysts commented, "We continue to see more likelihood of underappreciated value elsewhere in the Voyager pipeline. Yesterday, after the market close, Voyager Therapeutics announced Sanofi chose not to exercise its exclusive option to ex-US development and commercialization of AAV-based gene therapy (GT), VY-AADC, in aPD." (10/31/2017)

Who are some of Voyager Therapeutics' key competitors?

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the folowing people:
  • Dr. Steven M. Paul, CEO, Pres & Director (Age 67)
  • Dr. Dinah Sah Ph.D., Chief Scientific Officer (Age 57)
  • Dr. Robert G. Pietrusko Pharm. D., Sr. VP of Regulatory Affairs & Quality Assurance (Age 70)
  • Dr. Krystof Bankiewicz M.D., Ph.D., Founder
  • Dr. Guangping Gao Ph.D., Founder

Has Voyager Therapeutics been receiving favorable news coverage?

Media coverage about VYGR stock has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Voyager Therapeutics earned a media sentiment score of 0.12 on Accern's scale. They also gave news stories about the company an impact score of 47.74 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $17.85.

How big of a company is Voyager Therapeutics?

Voyager Therapeutics has a market capitalization of $617.73 million and generates $10.14 million in revenue each year. The company earns $-70,690,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Voyager Therapeutics employs 88 workers across the globe.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected]


MarketBeat Community Rating for Voyager Therapeutics (VYGR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  330
MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe VYGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Voyager Therapeutics (NASDAQ:VYGR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Voyager Therapeutics in the last 12 months. Their average twelve-month price target is $30.10, suggesting that the stock has a possible upside of 68.63%. The high price target for VYGR is $40.00 and the low price target for VYGR is $12.00. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.822.822.922.89
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.10$30.10$26.90$26.2857
Price Target Upside: 68.63% upside29.97% upside89.97% upside9.52% upside

Voyager Therapeutics (NASDAQ:VYGR) Consensus Price Target History

Price Target History for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2018Canaccord GenuitySet Price TargetBuy$35.00HighView Rating Details
3/12/2018WedbushDowngradeOutperform -> Neutral$29.00HighView Rating Details
3/12/2018Piper JaffrayReiterated RatingOverweight -> Buy$40.00HighView Rating Details
3/11/2018BTIG ResearchReiterated RatingBuy$32.00HighView Rating Details
2/21/2018Morgan StanleyBoost Price TargetOverweight -> Overweight$36.00 -> $39.00HighView Rating Details
10/31/2017Chardan CapitalReiterated RatingHold$17.00N/AView Rating Details
10/31/2017CowenReiterated RatingBuyN/AView Rating Details
10/30/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$31.00N/AView Rating Details
10/23/2017Stifel NicolausReiterated RatingBuy -> Buy$20.00 -> $31.00N/AView Rating Details
10/12/2017Raymond JamesInitiated CoverageOutperform -> Outperform$35.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$12.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$31.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
5/20/2016Wells FargoInitiated CoverageOutperformN/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Voyager Therapeutics (NASDAQ:VYGR) Earnings History and Estimates Chart

Earnings by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) Earnings Estimates

2018 EPS Consensus Estimate: ($2.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.68)($0.68)($0.68)
Q2 20181($0.70)($0.70)($0.70)
Q3 20181($0.71)($0.71)($0.71)
Q4 20181($0.73)($0.73)($0.73)

Voyager Therapeutics (NASDAQ VYGR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.39)N/AView Earnings Details
3/14/2018Q4 2017($0.72)($0.40)$5.81 million$6.35 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.72)($0.89)$1.26 million$1.15 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.62)($0.73)$3.27 million$1.18 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.54)($0.65)$3.70 million$1.46 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.46)($0.57)$4.15 million$2.36 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.41)($0.35)$4.36 million$3.31 millionViewN/AView Earnings Details
8/11/2016Q2($0.34)($0.37)$4.79 million$3.72 millionViewListenView Earnings Details
5/12/2016Q1($0.38)$0.29$5.00 million$4.83 millionViewListenView Earnings Details
3/17/2016Q4($0.55)($0.67)$5.00 million$4.94 millionViewListenView Earnings Details
12/17/2015Q3 2015($0.31)($5.25)$5.00 million$4.94 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Voyager Therapeutics (NASDAQ:VYGR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Voyager Therapeutics (NASDAQ VYGR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.00%
Institutional Ownership Percentage: 78.22%
Insider Trading History for Voyager Therapeutics (NASDAQ:VYGR)
Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ VYGR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/10/2018Bernard RavinaInsiderSell2,451$18.38$45,049.38View SEC Filing  
3/23/2018Jane HendersonCFOSell11,200$20.52$229,824.0019,900View SEC Filing  
3/19/2018Jane HendersonCFOSell17,316$22.11$382,856.7615,416View SEC Filing  
3/16/2018Jane HendersonCFOSell15,416$22.15$341,464.4015,416View SEC Filing  
3/12/2018Bernard RavinaInsiderSell2,451$25.16$61,667.16View SEC Filing  
2/27/2018Dinah Ph.D. SahInsiderSell15,623$30.00$468,690.00140,872View SEC Filing  
2/12/2018Bernard RavinaInsiderSell2,451$18.24$44,706.244,902View SEC Filing  
1/10/2018Bernard RavinaInsiderSell3,630$16.40$59,532.007,353View SEC Filing  
12/11/2017Bernard RavinaInsiderSell5,490$13.63$74,828.7010,983View SEC Filing  
11/10/2017Bernard RavinaInsiderSell5,490$13.26$72,797.4016,473View SEC Filing  
10/10/2017Bernard RavinaInsiderSell10,980$20.33$223,223.40View SEC Filing  
9/11/2017Bernard RavinaInsiderSell16,470$12.87$211,968.90View SEC Filing  
9/5/2017Bernard RavinaInsiderSell5,490$10.00$54,900.0017,157View SEC Filing  
7/20/2017Bernard RavinaInsiderSell5,490$10.00$54,900.00View SEC Filing  
1/14/2016Steven M PaulCEOBuy10,000$14.07$140,700.00872,351View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Voyager Therapeutics (NASDAQ VYGR) News Headlines

Source:
DateHeadline
Voyager Therapeutics (VYGR) Receives Average Rating of "Buy" from AnalystsVoyager Therapeutics (VYGR) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 19 at 3:33 PM
Voyager Therapeutics (VYGR) Downgraded by BidaskClubVoyager Therapeutics (VYGR) Downgraded by BidaskClub
www.americanbankingnews.com - April 19 at 10:42 AM
 Brokerages Expect Voyager Therapeutics (VYGR) Will Post Quarterly Sales of $3.17 Million Brokerages Expect Voyager Therapeutics (VYGR) Will Post Quarterly Sales of $3.17 Million
www.americanbankingnews.com - April 18 at 3:56 AM
Voyager Therapeutics (VYGR) Expected to Post Earnings of -$0.57 Per ShareVoyager Therapeutics (VYGR) Expected to Post Earnings of -$0.57 Per Share
www.americanbankingnews.com - April 16 at 11:18 AM
Voyager Therapeutics (VYGR) Downgraded by ValuEngineVoyager Therapeutics (VYGR) Downgraded by ValuEngine
www.americanbankingnews.com - April 15 at 10:59 AM
Voyager Therapeutics (VYGR) Insider Bernard Ravina Sells 2,451 SharesVoyager Therapeutics (VYGR) Insider Bernard Ravina Sells 2,451 Shares
www.americanbankingnews.com - April 12 at 4:33 PM
Voyager Therapeutics (VYGR) Upgraded to "Hold" by BidaskClubVoyager Therapeutics (VYGR) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - April 12 at 11:15 AM
Quotidian Technical Highlights on Selected Biotech Stocks -- Vertex Pharma, VIVUS, Voyager Therapeutics, and Zosano PharmaQuotidian Technical Highlights on Selected Biotech Stocks -- Vertex Pharma, VIVUS, Voyager Therapeutics, and Zosano Pharma
www.bizjournals.com - April 10 at 8:30 AM
Voyager Therapeutics (VYGR) Given a $35.00 Price Target by Canaccord Genuity AnalystsVoyager Therapeutics (VYGR) Given a $35.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 9 at 3:30 PM
Voyager Therapeutics (VYGR) Upgraded by ValuEngine to HoldVoyager Therapeutics (VYGR) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 2 at 10:22 PM
Voyager Therapeutics (VYGR) Stock Rating Lowered by ValuEngineVoyager Therapeutics (VYGR) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 1 at 2:04 PM
 Analysts Anticipate Voyager Therapeutics Inc (VYGR) Will Announce Quarterly Sales of $3.17 Million Analysts Anticipate Voyager Therapeutics Inc (VYGR) Will Announce Quarterly Sales of $3.17 Million
www.americanbankingnews.com - April 1 at 3:46 AM
Zacks: Analysts Anticipate Voyager Therapeutics Inc (VYGR) to Post -$0.57 EPSZacks: Analysts Anticipate Voyager Therapeutics Inc (VYGR) to Post -$0.57 EPS
www.americanbankingnews.com - March 30 at 1:18 PM
Jane Henderson Sells 11,200 Shares of Voyager Therapeutics Inc (VYGR) StockJane Henderson Sells 11,200 Shares of Voyager Therapeutics Inc (VYGR) Stock
www.americanbankingnews.com - March 26 at 4:10 PM
Voyager Therapeutics Inc (VYGR) Given Average Rating of "Buy" by BrokeragesVoyager Therapeutics Inc (VYGR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 25 at 3:36 PM
Voyager Therapeutics (VYGR) Downgraded by BidaskClub to "Sell"Voyager Therapeutics (VYGR) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - March 24 at 1:54 PM
Jane Henderson Sells 15,416 Shares of Voyager Therapeutics Inc (VYGR) StockJane Henderson Sells 15,416 Shares of Voyager Therapeutics Inc (VYGR) Stock
www.americanbankingnews.com - March 20 at 7:50 PM
Insider Selling: Voyager Therapeutics Inc (VYGR) CFO Sells 17,316 Shares of StockInsider Selling: Voyager Therapeutics Inc (VYGR) CFO Sells 17,316 Shares of Stock
www.americanbankingnews.com - March 20 at 7:50 PM
Voyager Therapeutics (VYGR) Downgraded by Zacks Investment Research to HoldVoyager Therapeutics (VYGR) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 20 at 1:50 PM
Voyager Therapeutics (VYGR) Upgraded at Zacks Investment ResearchVoyager Therapeutics (VYGR) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 16 at 3:06 PM
Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:18 AM
Voyager Therapeutics (VYGR) CEO Steve Paul on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaVoyager Therapeutics' (VYGR) CEO Steve Paul on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 15 at 8:18 AM
Voyager Therapeutics (VYGR) Announces Quarterly  Earnings Results, Beats Estimates By $0.32 EPSVoyager Therapeutics (VYGR) Announces Quarterly Earnings Results, Beats Estimates By $0.32 EPS
www.americanbankingnews.com - March 15 at 7:56 AM
Voyager Therapeutics Inc (VYGR) Insider Sells $61,667.16 in StockVoyager Therapeutics Inc (VYGR) Insider Sells $61,667.16 in Stock
www.americanbankingnews.com - March 14 at 8:11 PM
Canaccord Genuity Analysts Give Voyager Therapeutics (VYGR) a $35.00 Price TargetCanaccord Genuity Analysts Give Voyager Therapeutics (VYGR) a $35.00 Price Target
www.americanbankingnews.com - March 14 at 7:17 PM
Voyager Therapeutics, Inc. to Host Earnings CallVoyager Therapeutics, Inc. to Host Earnings Call
www.baystreet.ca - March 14 at 7:06 PM
Should You Buy Voyager Therapeutics (VYGR) Ahead of Earnings?Should You Buy Voyager Therapeutics (VYGR) Ahead of Earnings?
finance.yahoo.com - March 13 at 7:15 PM
 Analysts Expect Voyager Therapeutics Inc (VYGR) Will Announce Earnings of -$0.72 Per Share Analysts Expect Voyager Therapeutics Inc (VYGR) Will Announce Earnings of -$0.72 Per Share
www.americanbankingnews.com - March 13 at 11:49 AM
Wired News – Voyager Therapeutics Declared Longer-term Data from Phase-1b Trial Of VY-AADC for Advanced Parkinson’s DiseaseWired News – Voyager Therapeutics Declared Longer-term Data from Phase-1b Trial Of VY-AADC for Advanced Parkinson’s Disease
finance.yahoo.com - March 13 at 8:27 AM
Voyager Therapeutics (VYGR) Downgraded to Neutral at WedbushVoyager Therapeutics (VYGR) Downgraded to Neutral at Wedbush
www.americanbankingnews.com - March 12 at 9:22 PM
Piper Jaffray Companies Analysts Give Voyager Therapeutics (VYGR) a $40.00 Price TargetPiper Jaffray Companies Analysts Give Voyager Therapeutics (VYGR) a $40.00 Price Target
www.americanbankingnews.com - March 12 at 12:15 PM
Voyager Therapeutics (VYGR) Buy Rating Reaffirmed at BTIG ResearchVoyager Therapeutics' (VYGR) Buy Rating Reaffirmed at BTIG Research
www.americanbankingnews.com - March 11 at 12:40 PM
Voyager Therapeutics (VYGR) Downgraded to Hold at BidaskClubVoyager Therapeutics (VYGR) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - March 10 at 4:23 PM
Voyager Therapeutics (VYGR) Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced PDVoyager Therapeutics (VYGR) Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced PD
www.streetinsider.com - March 9 at 6:48 PM
Voyager Therapeutics announces data from Phase 1b trial of VY-AADC for advanced Parkinsons disease - Seeking AlphaVoyager Therapeutics announces data from Phase 1b trial of VY-AADC for advanced Parkinson's disease - Seeking Alpha
seekingalpha.com - March 9 at 8:21 AM
Voyager Therapeutics (VYGR) Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced PD - StreetInsider.comVoyager Therapeutics (VYGR) Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced PD - StreetInsider.com
www.streetinsider.com - March 9 at 8:21 AM
Voyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson’s DiseaseVoyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson’s Disease
finance.yahoo.com - March 9 at 8:21 AM
Voyager Therapeutics (VYGR) Set to Announce Quarterly Earnings on TuesdayVoyager Therapeutics (VYGR) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:32 AM
Citadel Advisors LLC Lowers Position in Voyager Therapeutics Inc (VYGR)Citadel Advisors LLC Lowers Position in Voyager Therapeutics Inc (VYGR)
www.americanbankingnews.com - March 2 at 5:40 AM
Voyager Therapeutics Inc (VYGR) Position Raised by Altrinsic Global Advisors LLCVoyager Therapeutics Inc (VYGR) Position Raised by Altrinsic Global Advisors LLC
www.americanbankingnews.com - March 2 at 4:10 AM
Dinah Ph.D. Sah Sells 15,623 Shares of Voyager Therapeutics Inc (VYGR) StockDinah Ph.D. Sah Sells 15,623 Shares of Voyager Therapeutics Inc (VYGR) Stock
www.americanbankingnews.com - March 1 at 9:46 PM
Recent Analysis Shows Mobile Mini, Corindus Vascular Robotics, Payment Data, STAAR Surgical, Voyager Therapeutics, and Sunshine Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows Mobile Mini, Corindus Vascular Robotics, Payment Data, STAAR Surgical, Voyager Therapeutics, and Sunshine Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - March 1 at 8:16 AM
Voyager Therapeutics Inc (VYGR) Receives Average Recommendation of "Buy" from BrokeragesVoyager Therapeutics Inc (VYGR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 28 at 5:50 PM
Aevitas Wealth Management Inc. Buys Shares of 84,323 Voyager Therapeutics Inc (VYGR)Aevitas Wealth Management Inc. Buys Shares of 84,323 Voyager Therapeutics Inc (VYGR)
www.americanbankingnews.com - February 28 at 4:06 AM
Voyager Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results and Corporate Highlights Conference CallVoyager Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results and Corporate Highlights Conference Call
finance.yahoo.com - February 27 at 5:54 PM
Voyager Therapeutics to Present at Cowen Health Care ConferenceVoyager Therapeutics to Present at Cowen Health Care Conference
finance.yahoo.com - February 26 at 5:44 PM
$5.81 Million in Sales Expected for Voyager Therapeutics Inc (VYGR) This Quarter$5.81 Million in Sales Expected for Voyager Therapeutics Inc (VYGR) This Quarter
www.americanbankingnews.com - February 26 at 4:38 AM
An Ear To The Pharma: 6 Stocks To Watch This Week - NasdaqAn Ear To The Pharma: 6 Stocks To Watch This Week - Nasdaq
www.nasdaq.com - February 25 at 8:40 AM
Victory Capital Management Inc. Invests $1.21 Million in Voyager Therapeutics Inc (VYGR)Victory Capital Management Inc. Invests $1.21 Million in Voyager Therapeutics Inc (VYGR)
www.americanbankingnews.com - February 25 at 5:52 AM
Voyager Therapeutics Inc (VYGR) Expected to Post Earnings of -$0.72 Per ShareVoyager Therapeutics Inc (VYGR) Expected to Post Earnings of -$0.72 Per Share
www.americanbankingnews.com - February 24 at 2:00 PM

SEC Filings

Voyager Therapeutics (NASDAQ:VYGR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Voyager Therapeutics (NASDAQ:VYGR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Voyager Therapeutics (NASDAQ VYGR) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.